Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changli Wei

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Nature Medicine|December 18, 2007
Modification of kidney barrier function by the urokinase receptorChangli Wei, Clemens C Möller, Mehmet M Altintas, et al.
Science Translational Medicine|June 3, 2011
Rituximab targets podocytes in recurrent focal segmental glomerulosclerosisAlessia Fornoni, Junichiro Sageshima, Changli Wei, et al.
Nature Medicine|December 13, 2016
Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney diseaseEunsil Hahm, Changli Wei, Isabel Fernandez, et al.
Nature Genetics|June 1, 2005
TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal functionJochen Reiser, Krishna R Polu, Clemens C Möller, et al.
Journal of the American Society of Nephrology : JASN|June 14, 2014
Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular diseaseTae-Hyun Yoo, Christopher E Pedigo, Johanna Guzman, et al.
Pediatric Research|January 20, 2019
MeSsAGe risk score: tool for renal biopsy decision in steroid-dependent nephrotic syndromeChang-Yien Chan, Lourdes Paula Resontoc, Md Abdul Qader, et al.
Journal of the American Society of Nephrology : JASN|January 10, 2015
Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical TrialJeffrey B Kopp, Cheryl A Winkler, Xiongce Zhao, et al.
Journal of the American Society of Nephrology : JASN|November 10, 2012
Circulating suPAR in two cohorts of primary FSGSChangli Wei, Howard Trachtman, Jing Li, et al.
Journal of the American Society of Nephrology : JASN|March 9, 2017
Targeting mTOR Signaling Can Prevent the Progression of FSGSStefan Zschiedrich, Tillmann Bork, Wei Liang, et al.
Kidney International|June 7, 2013
Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndromePietro Ravani, Alessandro Ponticelli, Chiara Siciliano, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Nature Medicine|December 18, 2007
Modification of kidney barrier function by the urokinase receptorChangli Wei, Clemens C Möller, Mehmet M Altintas, et al.
Science Translational Medicine|June 3, 2011
Rituximab targets podocytes in recurrent focal segmental glomerulosclerosisAlessia Fornoni, Junichiro Sageshima, Changli Wei, et al.
Nature Medicine|December 13, 2016
Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney diseaseEunsil Hahm, Changli Wei, Isabel Fernandez, et al.
Nature Genetics|June 1, 2005
TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal functionJochen Reiser, Krishna R Polu, Clemens C Möller, et al.
Journal of the American Society of Nephrology : JASN|June 14, 2014
Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular diseaseTae-Hyun Yoo, Christopher E Pedigo, Johanna Guzman, et al.
Pediatric Research|January 20, 2019
MeSsAGe risk score: tool for renal biopsy decision in steroid-dependent nephrotic syndromeChang-Yien Chan, Lourdes Paula Resontoc, Md Abdul Qader, et al.
Journal of the American Society of Nephrology : JASN|January 10, 2015
Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical TrialJeffrey B Kopp, Cheryl A Winkler, Xiongce Zhao, et al.
Journal of the American Society of Nephrology : JASN|November 10, 2012
Circulating suPAR in two cohorts of primary FSGSChangli Wei, Howard Trachtman, Jing Li, et al.
Journal of the American Society of Nephrology : JASN|March 9, 2017
Targeting mTOR Signaling Can Prevent the Progression of FSGSStefan Zschiedrich, Tillmann Bork, Wei Liang, et al.
Kidney International|June 7, 2013
Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndromePietro Ravani, Alessandro Ponticelli, Chiara Siciliano, et al.
Pageof 8